Related Experiment Video
Updated: Apr 19, 2026
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
Lung cancer in 2014: optimizing lung cancer treatment approaches
Rafael Rosell1, Niki Karachaliou2
1Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Carretera Canyet s/n, 08916 Badalona, Barcelona, Spain.
Abstract:
In 2014, developments in our understanding of escape signalling circuits implicated in resistance to targeted agents in patients with lung cancer have led to improvements in tackling such resistance. The potential role for PET in the management of erlotinib therapy, novel combination therapies and pharmacogenomic-driven individualization of platinum-based chemotherapy represent other key advances.
Insights
Advances in understanding lung cancer resistance mechanisms have improved treatment strategies. Key developments include targeting resistance pathways, using PET scans with erlotinib, and personalized platinum-based chemotherapy.
Area of Science:
- Oncology
- Pharmacology
- Medical Imaging
Background:
- Resistance to targeted therapies is a major challenge in lung cancer treatment.
- Understanding escape signaling circuits is crucial for overcoming drug resistance.
- Erlotinib is a targeted agent used in lung cancer therapy.
Purpose of the Study:
- To highlight key 2014 advancements in managing lung cancer resistance to targeted agents.
- To discuss the role of PET imaging in erlotinib therapy management.
- To explore novel combination therapies and personalized chemotherapy approaches.
Main Methods:
- Review of recent developments in lung cancer research and clinical practice.
- Analysis of studies on resistance mechanisms and therapeutic strategies.
- Inclusion of pharmacogenomic data for chemotherapy individualization.
Main Results:
- Improved understanding of escape signaling circuits has led to better resistance management.
- Positron Emission Tomography (PET) shows potential in managing erlotinib therapy.
- Novel combination therapies and personalized platinum-based chemotherapy are emerging as key advances.
Conclusions:
- Significant progress has been made in overcoming resistance to targeted lung cancer therapies.
- Personalized medicine approaches, including pharmacogenomics and advanced imaging, are transforming lung cancer treatment.
- Continued research into resistance mechanisms promises further therapeutic improvements.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:46A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer
Published on: August 19, 2025
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...